Comparative Pharmacology
Head-to-head clinical analysis: SUMATRIPTAN NAPROXEN SODIUM versus SUMATRIPTAN SUCCINATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUMATRIPTAN NAPROXEN SODIUM versus SUMATRIPTAN SUCCINATE.
SUMATRIPTAN; NAPROXEN SODIUM vs SUMATRIPTAN SUCCINATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sumatriptan is a selective 5-HT1B/1D receptor agonist, causing vasoconstriction of cranial blood vessels and inhibition of trigeminal nerve transmission. Naproxen sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial blood vessels and inhibits release of pro-inflammatory neuropeptides.
Sumatriptan 85 mg / naproxen sodium 500 mg orally at onset of migraine; may repeat once after 2 hours if needed, not to exceed 2 tablets in 24 hours.
50-100 mg orally at onset of migraine; may repeat after 2 hours if needed, max 200 mg/day. 6 mg subcutaneously as a single dose; may repeat after 1 hour if needed, max 12 mg/day. 20 mg intranasally as a single dose; may repeat after 2 hours if needed, max 40 mg/day.
None Documented
None Documented
Sumatriptan: terminal half-life approximately 2.5 hours (range 1.5–4.6 hours); clinically, short half-life limits duration of action. Naproxen sodium: terminal half-life approximately 12–17 hours (mean 14 hours); long half-life allows twice-daily dosing and sustained analgesic effect.
Terminal elimination half-life: approximately 2 hours (range 1–4 hours). Clinical context: Short half-life supports use for acute migraine attacks; no accumulation with standard dosing.
Sumatriptan: renal excretion of unchanged drug and metabolites (primarily indole acetic acid analogue) accounts for approximately 60% of elimination; fecal/biliary excretion accounts for about 40%. Naproxen sodium: renal excretion of unchanged drug (approximately 60%) and glucuronide conjugates (about 40%); less than 5% is excreted fecally.
Primarily renal (60% as unchanged drug and metabolites, 40% via feces); approximately 20% unchanged in urine. Minor biliary excretion.
Category D/X
Category D/X
5-HT1 Agonist
5-HT1 Agonist